DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. - Wikidata - awgldk - TriplyDB

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

http://www.wikidata.org/entity/Q52619102

about

Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Miniaturized embryo array for automated trapping, immobilization and microperfusion of zebrafish embryos Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach Integrated chip-based physiometer for automated fish embryo toxicity biotests in pharmaceutical screening and ecotoxicology.A zebrafish model of inflammatory lymphangiogenesis Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.Conservation and early expression of zebrafish tyrosine kinases support the utility of zebrafish as a model for tyrosine kinase biology.Assessment of biocompatibility of 3D printed photopolymers using zebrafish embryo toxicity assays.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Vascular-targeted agents for the treatment of angiosarcoma.OpenSource lab-on-a-chip physiometer for accelerated zebrafish embryo biotests.Microfluidic device for a rapid immobilization of zebrafish larvae in environmental scanning electron microscopy.

P2860

Q26751344-996340D4-F247-46E3-A255-D785AEC5479A Q27303464-92EA34DC-3E73-412F-8F32-451DDF00E8B4 Q28076161-CD106CAE-C8E6-42CB-ACA6-35A7B5DC79EA Q28388409-F16C33E8-FDA6-4A4A-9A2C-CF0DC2972192 Q35130368-87BCA7FF-94F8-4A51-8616-60417AF32F57 Q36175340-9A9FC7B9-6856-4D27-BC97-6E39B93721E9 Q36557347-CAFEDC42-1BAE-4013-BD20-D988FF443FB0 Q37139551-48C9B2E6-E41A-447A-8692-21524F2E9459 Q38543437-8D5B3DAE-47A7-4D3B-A318-92BA58330E3F Q38757723-65AE44B7-9989-47C7-85DE-67A2137738CE Q39061298-FA5169B6-3599-4853-8234-57D67C45D758 Q44304010-D60E75D7-4543-4C22-8657-7257F3AE0B0D Q45764944-62583921-22C1-4D37-8217-2850B429F9DD

P2860

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

http://www.wikidata.org/entity/Q52619102

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@en

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@nl

type

label

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@en

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@nl

prefLabel

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@en

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

@nl

P1433

Q52619102-B4B398C0-5B5A-444C-88AD-BD987D88280D

P1476

Q52619102-5CD25DCC-E177-4223-8754-EE8BF2A90329

P2093

Q52619102-1EE5436A-E956-481C-9988-390101A960BA

Q52619102-2659DB28-D428-4FF8-BE2C-C98886EC4674

Q52619102-2C314C24-727B-42C7-B977-43B05B2A67CB

Q52619102-66738A61-73DC-4582-A058-2BE808125D13

Q52619102-CB75016E-B9FF-4540-86EE-26E7E9A7C906

Q52619102-E2DC17FB-B4F0-459A-9546-827B4AEA0EDE

P2860

Q52619102-01BAFBC4-6C0D-472B-8F59-FED7D12E2FF5

Q52619102-05C5D3F2-0118-48F7-B3E1-46D24CB63374

Q52619102-16DE8CF6-44CA-41AF-9B7E-306E012E7668

Q52619102-26A40520-9EB4-4BF7-A3B1-303F7DD7DF31

Q52619102-275CCDA9-2F57-4D0E-9E88-152C26D0E9BE

Q52619102-2A240C8A-73E6-47B7-8184-B668399A0110

Q52619102-2C6C67AE-E193-4E55-A79D-D73DEDCDCE14

Q52619102-339E1B44-DA30-4606-817E-48538137B2D4

Q52619102-34DEE827-F3A1-4B62-85BC-7FCAE64BE3A2

Q52619102-3B20B911-EA6E-42D3-9A55-D9737F15DDA2

P304

Q52619102-D92EF34F-2726-4E2A-95AA-F427560634FD

P31

Q52619102-09BF3D7A-7F08-4932-A16D-858EDC50EA88

P356

Q52619102-FB13FDFF-C329-415C-9E95-244875E85CE2

P407

Q52619102-23860DFF-F6A7-49C3-AF79-2FF75766C22F

P433

Q52619102-F69EDD53-AEA4-414F-B66E-6CB55D96C5EB

P478

Q52619102-A177DB7B-E59F-4EB8-945C-7C0A3CB6ABBB

P50

Q52619102-A018550F-9F1B-4401-84B5-AA2E792C040C

P577

Q52619102-F4475A8E-EB49-470F-AB25-C521420CA930

P5875

Q52619102-98BEA700-8044-4994-BDC5-F3CDA70B2C38

P698

Q52619102-C56786FF-27AE-4C88-BA01-E6DA99A9F32A

P921

Q52619102-013735AB-0144-41D8-B988-CD9117A88356

P356

P1433

Clinical Science

P1476

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular

@en

P2093

Christina M Buchanan

http://www.w3.org/2001/XMLSchema#string

Gordon W Rewcastle

http://www.w3.org/2001/XMLSchema#string

Jack U Flanagan

http://www.w3.org/2001/XMLSchema#string

Jen-Hsing Shih

http://www.w3.org/2001/XMLSchema#string

Peter R Shepherd

http://www.w3.org/2001/XMLSchema#string

Philip S Crosier

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

The selectivity of protein kinase inhibitors: a further update

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase

Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2

Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

In vivo imaging of embryonic vascular development using transgenic zebrafish

P304

449-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/CS20110412

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan W. Astin

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51853462

http://www.w3.org/2001/XMLSchema#string

P698

22142330

http://www.w3.org/2001/XMLSchema#string

P921